Entering text into the input field will update the search result below

Seattle Genetics launches early-stage study of antibody-drug conjugate in multiple myeloma

Mar. 07, 2018 8:27 AM ETSeagen Inc. (SGEN) StockBy: Douglas W. House, SA News Editor
  • Dosing is underway in a Phase 1 clinical trial assessing the safety and activity of Seattle Genetics' (NASDAQ:SGEN) SGN-CD48A in 75 patients with relapsed/refractory multiple myeloma (MM). Patients will receive an intravenous infusion every three weeks.
  • The primary endpoints are safety and tolerability. Secondary endpoints will assess antitumor activity and will inform the recommended single-agent dose and regimen for subsequent studies.
  • SGN-CD48A, designed to be high stable in the body, is an antibody-drug conjugate targeting a cell surface protein called CD48 that is highly expressed in MM. The monoclonal antibody that binds to CD48 is linked to a cytotoxic agent called monomethyl auristatin E (MMAE).
  • According to ClinicalTrials.gov, the estimated primary completion date is August 2020.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SGEN--
Seagen Inc.